Nivolumab-associated hypopituitarism in a 61-year-old woman with metastatic triple-negative breast.

Ketevan Lomidze, Marine Gordeladze, Nino Kikodze, Nino Charkviani, Tinatin Chikovani

Abstract readCase Reports

In one paragraph

Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ketevan LomidzeDepartment of Immunology, Department of Endocrinology, Tbilisi State Medical University, Vazha-Pshavela Str. #33, Tbilisi 0186, Georgia.ORCID https://orcid.org/0000-0003-0929-7202

Marine GordeladzeDepartment of Endocrinology, Tbilisi State Medical University, Vazha-Pshavela Str. #33, Tbilisi 0186, Georgia.

Nino KikodzeDepartment of Immunology, Tbilisi State Medical University, Vazha-Pshavela Str. #33, Tbilisi 0186, Georgia.

Nino CharkvianiDepartment of Endocrinology, Tbilisi State Medical University, Vazha-Pshavela Str. #33, Tbilisi 0186, Georgia.

Tinatin ChikovaniDepartment of Immunology, Tbilisi State Medical University, Vazha-Pshavela Str. #33, Tbilisi 0186, Georgia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of cancer, enhancing response rates and survival outcomes. However, immune-related adverse events (irAEs), which can affect any organ or system, can limit their use. We report a rare case of hypophysitis in a triple-negative breast cancer patient receiving nivolumab, an anti-PD-1 monoclonal antibody. After six infusions of nivolumab, the patient developed hypocortisolism and hypothyroidism symptoms, such as mood swings, fatigue, unintentional weight loss, and vomiting. The diagnosis was confirmed by laboratory testing. The patient was successfully managed with hormone replacement therapy. Endocrinopathies can be life-threatening, necessitating treating doctors recognise their clinical symptoms, diagnose them, and manage them to ensure effective treatment and enhance the outcomes of immune checkpoint inhibitor-induced endocrine adverse effects.

Indexed as

adrenal insufficiencybreast neoplasmscase reportHypophysitisnivolumab

Identifiers

PMID42117132

DOI10.1093/omcr/omag060

PMCPMC13157630

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.